1. P1086: FAVEZELIMAB (ANTI–LAG-3) AND PEMBROLIZUMAB CO-BLOCKADE IN ANTI–PD-1–NAIVE PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA: AN OPEN-LABEL PHASE 1/2 STUDY. (23rd June 2022) Authors: Gregory, G.; Timmerman, J.; Lavie, D.; Borchmann, P.; Herrera, A. F.; Minuk, L.; Vucinic, V.; Armand, P.; Avigdor, A.; Gasiorowski, R.; Herishanu, Y.; Keane, C.; Kuruvilla, J.; Palcza, J.; Pillai, P.; Marinello, P.; Johnson, N. A. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 976 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P1087: FAVEZELIMAB (ANTI–LAG-3) AND PEMBROLIZUMAB CO-BLOCKADE IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA WHO PROGRESSED AFTER ANTI–PD-1 THERAPY: AN OPEN-LABEL PHASE 1/2 STUDY. (23rd June 2022) Authors: Herrera, A. F.; Lavie, D.; Johnson, N. A.; Avigdor, A.; Borchmann, P.; Andreadis, C.; Bazargan, A.; Gregory, G.; Keane, C.; Inna, T.; Vucinic, V.; Zinzani, P. L.; Zhang, H.; Pillai, P.; Marinello, P.; Timmerman, J. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 977 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P1190: OUTCOMES BY BCL2 AND MYC EXPRESSION AND REARRANGEMENTS IN UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA FROM THE POLARIX TRIAL. (23rd June 2022) Authors: Morschhauser, F.; Jiang, Y.; Jardin, F.; Herrera, A. F.; Sehn, L. H.; Herbaux, C.; Flowers, C.; Phillips, T.; López Guillermo, A.; Diefenbach, C.; Gregory, G. P.; Kim, A.; Barbui, A. M.; Balasubramanian, S.; Harris, W.; Hirata, J.; Paulson, J. N.; Lee, C.; Lenz, G. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1076 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P1351: CHARACTERIZING ALLOGENEIC STEM CELL TRANSPLANTATION SAFETY IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES AFTER PEMBROLIZUMAB THERAPY. (23rd June 2022) Authors: Kuruvilla, J.; Armand, P.; Herrera, A. F.; Ribrag, V.; Brice, P.; Thieblemont, C.; Von Tresckow, B.; Kim, E.; Marinello, P.; Chakraborty, S.; Orlowski, R.; Zinzani, P. L. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1236 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. S201: CAMIDANLUMAB TESIRINE: UPDATED EFFICACY AND SAFETY IN AN OPEN-LABEL, MULTICENTER, PHASE 2 STUDY OF PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL). (23rd June 2022) Authors: Carlo-Stella, C.; Ansell, S.; Zinzani, P. L; Radford, J.; Maddocks, K.; Pinto, A.; Collins, G. P.; Bachanova, V.; Bartlett, N.; Bence-Bruckler, I.; Hamadani, M.; Kline, J.; Mayer, J.; Savage, K. J.; Advani, R.; Caimi, P.; Casasnovas, R.-O.; Feldman, T.; Hess, B.; Bastos-Oreiro, M. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 102 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗